The NSABP Study of Tamoxifen and Raloxifene (STAR) trial

@article{Vogel2009TheNS,
  title={The NSABP Study of Tamoxifen and Raloxifene (STAR) trial},
  author={V. Vogel},
  journal={Expert Review of Anticancer Therapy},
  year={2009},
  volume={9},
  pages={51 - 60}
}
  • V. Vogel
  • Published 2009
  • Medicine
  • Expert Review of Anticancer Therapy
In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years. There were an equal number of cases of invasive breast cancer in women assigned to tamoxifen and raloxifene. There were fewer cases of noninvasive breast cancer in the tamoxifen group than in the raloxifene group (risk ratio [RR]: 1.40; 95% confidence interval [CI]: 0.98–2.02). There were more cases of… Expand
Effects of Raloxifene Combined with Low-dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer
TLDR
Combined raloxifene and low-dose CE decreased the severity of menopausal symptoms to a similar extent as CE alone and had similar effects as ral oxifene alone on the endometrium. Expand
Raloxifene for older women: a review of the literature
TLDR
Raloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which is used for prevention and treatment of postmenopausal osteoporosis and as effective as tamoxifen in reducing the risk of invasive breast cancer. Expand
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women.
TLDR
No evidence exists establishing whether a reduction in breast cancer risk from either agent translates into reduced breast cancer mortality, and overall quality of life is similar with raloxifene or tamoxifen, but the incidence of dyspareunia, weight gain, and musculoskeletal complaints is higher with rAloxifenes use, whereas vasomotor symptoms, bladder incontinence, gynecologic symptoms, and leg cramps were higher with tamoxIFen use. Expand
Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease
TLDR
In postmenopausal women at increased risk for coronary events, the incidences of venous thromboembolism and fatal stroke but not all strokes were higher in those assigned raloxifene versus placebo, except that the risk of stroke differed by smoking status. Expand
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density.
TLDR
This pilot study supports the use of letrozole for reducing breast cancer risk and encourages prospective studies of serial changes in mammographic density as a biomarker of risk modification within a selected high-risk population. Expand
Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates
TLDR
Raloxifene patients were younger, had better overall health status and appeared to have risk factors for new osteoporotic fractures than bisphosphonate patients, and differences remained statistically significant in the multivariate model. Expand
Adjuvant Surgical Oophorectomy Plus Tamoxifen: NewEfficacy and Secondary Effects Data
Recent publication of the 8-year update of the SOFT and TEXT trials indirectly calls attention to the leading role that surgical oophorectomy plus tamoxifen (SO+T) should now play in global breastExpand
Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells
TLDR
Results showed that RAL could significantly sensitize ER- MDR breast tumors to paclitaxel both in vitro and in vivo and suggested that raloxifene might be a valuable chemosensitizer agent for breast cancer therapy. Expand
The impact of tamoxifen brand switch on side effects and patient compliance in hormone receptor positive breast cancer patients.
TLDR
Severe tamoxifen side effects are commonly experienced by breast cancer patients and can be significantly altered by change in tamoxIFen brand. Expand
Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
TLDR
BZA was associated with a favorable reproductive safety profile in postmenopausal women with osteoporosis over 7 years and this was a second, blinded, 2-year extension of a 3-year, randomized, double-blind, placebo (PBO)- and active-controlled phase 3 trial. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation
TLDR
Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increase risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrian cancer. Expand
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
TLDR
The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis, and no new safety concerns related to ral oxifene therapy were identified during CORE. Expand
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
TLDR
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
TLDR
The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke. Expand
Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk
TLDR
Raloxifene therapy was associated with a reduced risk of invasive breast cancer in postmenopausal women irrespective of the presence/absence of risk factors; its effect was greater in women with a family history of breast cancer. Expand
Raloxifene: a review of its use in postmenopausal osteoporosis.
TLDR
The lack of stimulatory effects on the endometrium and the reduction in invasive breast cancer incidence indicate raloxifene as an attractive alternative to HRT for the management of postmenopausal osteonorosis. Expand
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
TLDR
An extended follow-up of the Italian Randomized Tamoxifen Prevention Trial shows that appropriate selection of women at high risk for hormone receptor-positive (HR+) disease may improve the risk-benefit ratio of tamoxIFen intervention. Expand
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
TLDR
Prophylactic use of tamoxifen is contraindicated in women at high risk of thromboembolic disease and the combined evidence indicates that mortality from non-breast-cancer causes is not increased by tamoxIFen. Expand
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
TLDR
Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Expand
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
TLDR
No significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health, mental health, and depression, although the tamxifen group reported better sexual function. Expand
...
1
2
3
4
5
...